Summary
Overview
Work History
Education
Skills
Affiliations
Timeline
Generic
Andrew Curtis

Andrew Curtis

Bethlehem,PA

Summary

Results-driven, entrepreneurial life science executive, laser-focused on delivering patient and shareholder value. Demonstrable track record of building new businesses and initiatives across multiple therapeutic areas, specifically in rare diseases and Oncology.

Overview

29
29
years of professional experience

Work History

Chief Business and Strategy Officer

Nerviano Medical Sciences
08.2022 - 05.2023
    • Led creation of NMS' CRO and CDMO business plans to support out-licensing/sale initiative. CRO sold to Frontage in 2023
    • Staffed and trained NMS' nascent Oncology BD team, closing three development agreements in four months.

Vice President, Business Development

GNS Healthcare (now Atria)
11.2020 - 07.2022
  • Focusing on top five pharmaceutical and biotechnology companies, secured six research projects, deploying Atria's causal AI in silico digital twin technology, utilizing proteogenomic, RWE, and patient data to more efficiently design drug and biomarker clinical studies.

Vice President, Business Development

Suda Pharmaceuticals
03.2018 - 12.2019
  • Successfully closed two research agreements with Sanofi and Teva to utilize Suda's novel buccal lining reformulation technology, creating a spray mist to more efficiently administer solid oral dose medications.

Head, Corporate Strategy and Business Development

Affimed
01.2015 - 11.2017
    • Secured two academic research and commercialization agreements (MD Anderson and Sloan Kettering). Signed an additional research collaboration with a leading immuno-oncology company (unnamed).
    • Led the revamp of Affimed's NK antibody portfolio to create a more focused, balanced portfolio of early and mid-stage assets.

Founder

Rising Tide Therapeutics
09.2014 - 01.2015
    • In partnership with the Alpha-1/COPD Foundation, founded rare disease newco focused on developing a gene therapy cure for alpha anti-trypsin deficiency. Unable to progress the Company due to technical failures.

Head, External Opportunities

Pfizer Specialty Care
03.2012 - 01.2015
  • Led search, evaluation, and transaction team to identify new whitespace and adjacency opportunities.
  • Built business cases and Bard presentations for new initiatives in Advanced Wound Healing and Specialty Pain to support existing core Pfizer businesses

Executive Director, R&D Innovation and Strategy

Pfizer BioTherapeutics R&D
02.2010 - 03.2012
  • Led team that redesigned Pfizer's biologics research efforts by creating smaller, more focused entrepreneurial research units, by positioning the CSO as the CEO of each therapeutic unit, creating greater autonomy and focus. Led Pfizer's relocation from Alewife to Cambridge's burgeoning biotech community.
  • Developed a novel service model newco to provide under-utilized drug development services and capabilities, funding, and assets to VC-backed biotech companies via a co-funded, option-based exit strategy.

Team Lead, Rare Disease and Biosimilar Commercial

Pfizer Established Products
10.2008 - 02.2010
    • Led team team developing two new business initiatives for Rare Diseases and Biosimilars. Gained Pfizer Board approval and funding to support initiative.
    • Public communication of Pfizer initiative boosted stock value by 2.5% (>$5B)
    • In-licensed Protalix's 1st plant cell-based therapy for Gaucher's disease (Elelyso), growing WW market to $1.2B, including accessing Brazil market via annualized $75m tech-transfer
    • Acquired FoldRx, acquiring Tafamadis (TTR), launching to exceed $1B
    • Constructed an internal pipeline of 12 biosimilar development programs
    • Signed deal to license Biocon's five diabetes therapies

US General Manager

Jerini US
02.2006 - 10.2008
  • Built and led US commercial team (Medical, Scientific Affairs, Marketing, Reimbursement, Advocacy, etc.), successfully developing Hereditary Angioedema market in preparation for launch of icatibant, ultimately launching to successful annualized sales of ~$650 in US.

Director, US Aricept Marketing

Pfizer
01.2003 - 02.2006
    • Led US Aricept team to generate in excess of $1B (2005) for this marginal brand. P&L responsibility.

Director, Advanced Wound Care Commercialization

J&J Ethicon
11.2000 - 02.2003
    • Led all commercialization and alliance management efforts to support biological wound healing therapy to treat severe burns, wounds, and tissue fillers.

Director, Commercial Development

Genzyme
01.1996 - 02.2000
    • Responsible for Genzyme's LSD commercial development of therapies for Pompe's and Fabry's diseases. Led all patient advocacy, pricing, distribution strategies for both programs.

Market Development Associate

Merck
06.1994 - 04.1996
    • Established two Women's Canters of Excellence (St. Barnabas/Overlook Hospital) in support of early osteoporosis detection and treatment with Fosamax.

Education

Master of Arts - Government

Lehigh University
Bethlehem
05.1994

Bachelor of Arts - Political Science

Muhlenberg College
Allentown, PA
05.1992

Skills

  • Team building
  • Critical Thinking
  • Supervision and leadership
  • Decision-Making
  • Task Prioritization
  • Relationship Building
  • Problem-Solving
  • Innovation and Entrepreneurship

Affiliations

  • NORD Corporate Council
  • Alpha-1 Foundation Board

Timeline

Chief Business and Strategy Officer

Nerviano Medical Sciences
08.2022 - 05.2023

Vice President, Business Development

GNS Healthcare (now Atria)
11.2020 - 07.2022

Vice President, Business Development

Suda Pharmaceuticals
03.2018 - 12.2019

Head, Corporate Strategy and Business Development

Affimed
01.2015 - 11.2017

Founder

Rising Tide Therapeutics
09.2014 - 01.2015

Head, External Opportunities

Pfizer Specialty Care
03.2012 - 01.2015

Executive Director, R&D Innovation and Strategy

Pfizer BioTherapeutics R&D
02.2010 - 03.2012

Team Lead, Rare Disease and Biosimilar Commercial

Pfizer Established Products
10.2008 - 02.2010

US General Manager

Jerini US
02.2006 - 10.2008

Director, US Aricept Marketing

Pfizer
01.2003 - 02.2006

Director, Advanced Wound Care Commercialization

J&J Ethicon
11.2000 - 02.2003

Director, Commercial Development

Genzyme
01.1996 - 02.2000

Market Development Associate

Merck
06.1994 - 04.1996

Master of Arts - Government

Lehigh University

Bachelor of Arts - Political Science

Muhlenberg College
Andrew Curtis